TY - JOUR
T1 - Inhibition of hepatitis B virus expression and replication by RNA interference
AU - Shlomai, Amir
AU - Shaul, Yosef
N1 - Funding Information:
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; RNAi, RNA interference; dsRNA, double-stranded RNA; mRNA, messenger RNA; siRNA, small interfering RNA; pSUPER, suppression of endogenous RNA; GFP, green fluorescent protein; EGFP, enhanced green fluorescent protein; PBS, phosphate-buffered saline; HBsAg, HBV surface antigen. From the 1Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. Received October 23, 2002; accepted January 22, 2003. Supported by a grant from Israel Ministry of Health. Address reprint requests to: Yosef Shaul, Ph.D., Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel. E-mail: [email protected]; fax: (972) 8-934-4108. Copyright © 2003 by the American Association for the Study of Liver Diseases. 0270-9139/03/3704-0009$30.00/0 doi:10.1053/jhep.2003.50146
PY - 2003/4/1
Y1 - 2003/4/1
N2 - RNA interference (RNAi) is the process of sequence-specific gene silencing, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the target gene. Because it has been shown that RNAi can be accomplished in cultured mammalian cells by introducing small interfering RNAs (siRNAs), much effort has been invested in exploiting this phenomenon for experimental and therapeutic means. In this study, we present a series of experiments showing a significant reduction in hepatitis B virus (HBV) transcripts and proteins in cell culture, as well as in the viral replicative forms, induced by siRNA-producing vectors. The antiviral effect is sequence-specific and does not depend on active viral replication. In conclusion, our data suggest that RNAi may provide a powerful therapeutic tool, acting both on replication-competent and on replication-incompetent HBV.
AB - RNA interference (RNAi) is the process of sequence-specific gene silencing, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the target gene. Because it has been shown that RNAi can be accomplished in cultured mammalian cells by introducing small interfering RNAs (siRNAs), much effort has been invested in exploiting this phenomenon for experimental and therapeutic means. In this study, we present a series of experiments showing a significant reduction in hepatitis B virus (HBV) transcripts and proteins in cell culture, as well as in the viral replicative forms, induced by siRNA-producing vectors. The antiviral effect is sequence-specific and does not depend on active viral replication. In conclusion, our data suggest that RNAi may provide a powerful therapeutic tool, acting both on replication-competent and on replication-incompetent HBV.
UR - http://www.scopus.com/inward/record.url?scp=0037382795&partnerID=8YFLogxK
U2 - 10.1053/jhep.2003.50146
DO - 10.1053/jhep.2003.50146
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 12668968
AN - SCOPUS:0037382795
SN - 0270-9139
VL - 37
SP - 764
EP - 770
JO - Hepatology
JF - Hepatology
IS - 4
ER -
